| 000 | 01592 a2200457 4500 | ||
|---|---|---|---|
| 005 | 20250513101123.0 | ||
| 264 | 0 | _c19961112 | |
| 008 | 199611s 0 0 eng d | ||
| 022 | _a0269-2813 | ||
| 024 | 7 |
_a10.1111/j.1365-2036.1995.tb00438.x _2doi |
|
| 040 |
_aNLM _beng _cNLM |
||
| 100 | 1 | _aThomson, A B | |
| 245 | 0 | 0 |
_aMesalazine (Mesasal/Claversal) 1.5 g b.d. vs. placebo in the maintenance of remission of patients with Crohn's disease. _h[electronic resource] |
| 260 |
_bAlimentary pharmacology & therapeutics _cDec 1995 |
||
| 300 |
_a673-83 p. _bdigital |
||
| 500 | _aPublication Type: Clinical Trial; Comparative Study; Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't | ||
| 650 | 0 | 4 | _aAdult |
| 650 | 0 | 4 | _aAged |
| 650 | 0 | 4 |
_aAminosalicylic Acids _xadverse effects |
| 650 | 0 | 4 |
_aAnti-Inflammatory Agents, Non-Steroidal _xtherapeutic use |
| 650 | 0 | 4 | _aCanada |
| 650 | 0 | 4 |
_aColitis _xdrug therapy |
| 650 | 0 | 4 |
_aCrohn Disease _xdrug therapy |
| 650 | 0 | 4 | _aDouble-Blind Method |
| 650 | 0 | 4 | _aEurope |
| 650 | 0 | 4 | _aFemale |
| 650 | 0 | 4 | _aHumans |
| 650 | 0 | 4 |
_aIleitis _xdrug therapy |
| 650 | 0 | 4 | _aMale |
| 650 | 0 | 4 | _aMesalamine |
| 650 | 0 | 4 | _aMiddle Aged |
| 650 | 0 | 4 | _aSouth Africa |
| 700 | 1 | _aWright, J P | |
| 700 | 1 | _aVatn, M | |
| 700 | 1 | _aBailey, R J | |
| 700 | 1 | _aRachmilewitz, D | |
| 700 | 1 | _aAdler, M | |
| 700 | 1 | _aWilson-Lynch, K A | |
| 773 | 0 |
_tAlimentary pharmacology & therapeutics _gvol. 9 _gno. 6 _gp. 673-83 |
|
| 856 | 4 | 0 |
_uhttps://doi.org/10.1111/j.1365-2036.1995.tb00438.x _zAvailable from publisher's website |
| 999 |
_c8818886 _d8818886 |
||